title: Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial.
abstract: OBJECTIVE
  To assess the effect of sulfasalazine (SSZ) on inflammatory back pain (IBP) due to active undifferentiated spondyloarthritis (uSpA) or ankylosing spondylitis in patients with symptom duration <5 years.
  
  
  METHODS
  Patients with IBP and a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) >3 from 12 centres were randomly assigned to 24 weeks' treatment with SSZ 2 g/day or placebo. The primary outcome variable was the change in BASDAI over 6 months. Secondary outcomes included measures of spinal pain, physical function and inflammation.
  
  
  RESULTS
  230 patients (50% men, age range 18-64 years, 67% human leucocyte antigen B27 positive) were treated with either SSZ 2x1 g/day or placebo for 6 months. Enthesitis was found in 50%, and peripheral arthritis in 47% of the patients. The mean (SD) BASDAI dropped markedly in both groups: by 3.7 (2.7) and 3.8 (2.4), respectively, as did most secondary outcome measures. No noticeable difference in treatment was observed between groups. Patients with IBP and no peripheral arthritis had significantly (p = 0.03) more benefit with SSZ (BASDAI 5.1 (1.3) to 2.8 (2.3)) than with placebo (5.2 (1.6) to 3.8 (2.4)). Spinal pain (p = 0.03) and morning stiffness (p = 0.05) improved with SSZ in these patients, but other secondary outcomes were not markedly different.
  
  
  CONCLUSIONS
  SSZ was no better than placebo for the treatment of the signs and symptoms of uSpA; however, SSZ was more effective than placebo in the subgroup of patients with IBP and no peripheral arthritis.
authors.affiliation: Rheumazentrum-Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany. J.Braun@rheumazentrum-ruhrgebiet.de
authors.forename: J
authors.initials: J
authors.lastname: Braun
authors.forename: J
authors.initials: J
authors.lastname: Zochling
authors.forename: X
authors.initials: X
authors.lastname: Baraliakos
authors.forename: R
authors.initials: R
authors.lastname: Alten
authors.forename: G
authors.initials: G
authors.lastname: Burmester
authors.forename: K
authors.initials: K
authors.lastname: Grasedyck
authors.forename: J
authors.initials: J
authors.lastname: Brandt
authors.forename: H
authors.initials: H
authors.lastname: Haibel
authors.forename: M
authors.initials: M
authors.lastname: Hammer
authors.forename: A
authors.initials: A
authors.lastname: Krause
authors.forename: F
authors.initials: F
authors.lastname: Mielke
authors.forename: H-P
authors.initials: HP
authors.lastname: Tony
authors.forename: W
authors.initials: W
authors.lastname: Ebner
authors.forename: B
authors.initials: B
authors.lastname: Gömör
authors.forename: J
authors.initials: J
authors.lastname: Hermann
authors.forename: H
authors.initials: H
authors.lastname: Zeidler
authors.forename: E
authors.initials: E
authors.lastname: Beck
authors.forename: M
authors.initials: M
authors.lastname: Baumgaertner
authors.forename: J
authors.initials: J
authors.lastname: Sieper
mesh_terms: D000293:Adolescent; D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001416:Back Pain / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D025241:Spondylarthritis / Q000150:complications / Q000188:drug therapy*; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy; D012460:Sulfasalazine / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D012460:Sulfasalazine